Guideline-discordant androgen deprivation therapy in localized prostate cancer: patterns of use in the medicare population and cost implications.
about
Considerations for observational research using large data sets in radiation oncologyHigh PSA anxiety and low health literacy skills: drivers of early use of salvage ADT among men with biochemically recurrent prostate cancer after radiotherapy?Are Small Reimbursement Changes Enough to Change Cancer Care? Reimbursement Variation in Prostate Cancer Treatment.The Use of Androgen Deprivation Therapy (ADT) and Chemotherapeutic Agents in New Zealand Men with Prostate Cancer.Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer.Treatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence.Patterns of prescription and adherence to European Association of Urology guidelines on androgen deprivation therapy in prostate cancer: an Italian multicentre cross-sectional analysis from the Choosing Treatment for Prostate Cancer (CHOICE) study.Dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events.Discrepancies on the association between androgen deprivation therapy for prostate cancer and subsequent dementia: meta-analysis and meta-regression.Prostate cancer: stratifying intermediate-risk patients for radiotherapy.Trans-Pacific variation in outcomes for men treated with primary androgen-deprivation therapy (ADT) for prostate cancer.
P2860
Q24289442-D41188CC-211F-4AB9-B9E8-AE5F067821D5Q35775237-A636C076-12DA-47D4-8BA3-7F3B29FB381FQ37125012-8987C57C-36E6-4952-918B-FC878EABBC40Q37596760-97EB5CBB-3E76-4542-8A33-16BD69042F57Q37712068-DC5BD7B8-EE0B-4A15-A150-9C31B0801E7DQ38653262-816DDAE1-4B6A-4373-99DA-236BF1798AF7Q41430910-DF3E991E-1797-4BBF-9642-1788840EE683Q41669642-B87278C8-6E6B-4991-8442-E79D25C59F52Q42700699-61E0768B-D293-4DC6-AF9A-0619D3BAE16AQ44592335-37F523A5-4A98-4B01-B1FF-99B046BF547EQ46772110-AE8F4801-F6E8-4E5E-8048-53A3542F61CA
P2860
Guideline-discordant androgen deprivation therapy in localized prostate cancer: patterns of use in the medicare population and cost implications.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Guideline-discordant androgen ...... ulation and cost implications.
@ast
Guideline-discordant androgen ...... ulation and cost implications.
@en
type
label
Guideline-discordant androgen ...... ulation and cost implications.
@ast
Guideline-discordant androgen ...... ulation and cost implications.
@en
prefLabel
Guideline-discordant androgen ...... ulation and cost implications.
@ast
Guideline-discordant androgen ...... ulation and cost implications.
@en
P2093
P2860
P356
P1433
P1476
Guideline-discordant androgen ...... ulation and cost implications.
@en
P2093
A R Kuykendal
L H Hendrix
P A Godley
R G Salloum
P2860
P304
P356
10.1093/ANNONC/MDS618
P577
2012-12-30T00:00:00Z